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Positron Emission Tomography and 
Magnetic Resonance Spectroscopy of 
Cerebral Glycolysis in Children with 
Congenital Lactic Acidosis
D. B. Duncan, MD,* K. Herholz, MD,* H. Kugel, PhD,t B. Roth, MD,t W. Ruitenbeek, PhD,§
W. Heindel, MD,f K. Wienhard, PhD,* and W.-D. Heiss, MD
Congenital lactic acidosis with neurological symptoms may be due to a variety of disorders of energy metabolism. We 
investigated whether positron emission tomography (PET) and proton magnetic resonance spectroscopy ('H MRS) are 
capable of demonstrating specific changes to facilitate diagnosis. A corresponding increase of cerebral lactate (with 
MRS) and rate of glycolysis (with PET) was observed in 2 children with biochemical evidence of defective mitochon­
drial respiration. No such increase was noted in a child with lactic acidosis due to stress and exercise but normal 
respiratory chain activity, and in a control case with an epilepsy syndrome without evidence of primary changes of 
energy metabolism. The results suggest that defects of oxidative phosphorylation may cause a massive increase of 
glycolysis to cover energy requirements, with corresponding accumulation of lactate in brain tissue. This mechanism 
can now be demonstrated in vivo and, with further experience, may potentially be used as a diagnostic marker of 
respiratory chain disorders in brain tissue.
■
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Congenital lactic acidosis (CLA) is a symptom that can 
occur as a result of an inborn error in the pathway 
responsible for the metabolism of pyruvate. Common 
etiologies include defects of the pyruvate dehydroge­
nase complex, pyruvate carboxylase, mitochondrial re­
spiratory chain enzymes, or the Krebs cycle {1, 2]. The 
accompanying clinical signs and symptoms may vary 
considerably depending on the type and the severity 
o f defect. Diagnosis is usually based on biochemical, 
radiological, and pathological studies. However, evalu­
ation is often invasive, time consuming, and is not al­
ways conclusive.
Positron emission tomography (PET) has been used 
in the evaluation of mitochondrial diseases because it 
provides a quantitative tracer method for regional mea­
surements of glucose and oxygen metabolism in brain 
tissue as well as blood flow. A study using 2- 
fluoro-2-deoxyglucose (FDG), [150 ]  oxygen, and [150 ]  
carbon dioxide in a series of adult patients with mito­
chondrial encephalomyopathy showed an altered stoi- 
chiometry in glucose and oxygen utilization resulting 
from aerobic glycolysis to lactate {3}. A similar study
4
examining patients with a clinical phenotype of CLA 
known bv the acronvm MERRF for myoclonus
lepsy and ragged-red fibers [4], however, revc 
signs of increased aerobic glycolysis. These 
found a chronically low rate of oxidative metabolism 
[5]. An adult patient with a mitochondrial encephalo-
» Amyopathy (probable MERRF) also showed a 
decrease in the cerebral metabolic rate of glucose
(CMRa{[.) [6]
be in the
examination of normal and abnorm
_*nt is image-g proton mag-
ne tic resonance spectroscopy (lH  MRS). The infor­
mation obtained from localized proton MR spectros-
copy can supplemented by information on
spatial distribution of metabolites using 1H MR speo
troscopic imaging (SI). In several studies [7—10] in­
creased peaks for lactate have been described in chil­
dren with Leigh disease [11], a form of CLA that can 
be caused by a defect in oxidative phosphorylation or 
pyruvate metabolism.
FDG PET and lH MRS are complementary with
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Table 1. CMRfi/i. (fxmolllOO g/min) in Major Brain Regions, Compared with Age-adjusted Reference Values
Diagnosis
Case 1
(Cerebral
Palsy)
Case 2 
(Possible 
Complex IV 
Defect)
Reference 
V alues3
Case 3 
(Complex I 
Defect)
Case 4
(Congenital
Epilepsy
Syndrome)
Reference 
V aluesil
Age 20 mo 14 mo 1—2 yr 2 wk 1 mo Birth to 1 yr
Cerebral hemisphere 15.53 53.13 27.36 ±  6.46 96.43 19.30 20.35 ±  4.79
Frontal cortex 15.76 48.13 29.65 ± 7.30 84.57 18.20 19.68 ±  4.84
Parietal cortex 16.88 54.86 28.76 ± 7.08 87.79 19.22 20.23 ± 5.03
Temporal cortex 15.85 55.63 28.67 ±  8.54 82.29 20.29 20.00 ±  4.23
Occipital cortex 15.86 59.65 30.39 ±  7.00 78.58 17.55 20.54 ±  5.08
Sensorimotor cortex 17.13 50.26 29.73 ± 7.44 103.02 21.51 22.17 ±  5.11
Anterior cingulate cortex 15.73 54.86 29.61 ± 6.40 108.62 21.60 20.53 ±  4.89
Caudate nuclei 8.67 69.81 28.77 ± 7.34 189.70 20.08 22.95 ± 7.06
>
Lenticular nuclei 14.04 81.51 32.36 ± 8.04 199.24 26.16 26.42 ± 7.14
Thalamus 14.00 39.40 29.48 ±  5.90 216.96 19.03 27.15 ± 7.86
Cerebellar cortex 15.61 2 6.66 19.50 ±  5.00 77.24 17.60 17.59 ± 2.70
Brainstem 12.53 37.11 21.17 ±  3.60 145.10 23.09 18.63 ± 3.81
“Mean ± SD, from Chugani and colleagues (1987).
regard to investigating the rate of glycolysis. The for­
mer basically measures the rate of FDG phosphoryla­
tion by hexokinase, which is nearly irreversible and 
therefore reflects total, oxidative and nonoxidative, gly­
colytic activity; the latter assesses lactate, which is the 
principal product of nonoxidative glycolysis. We there­
fore performed both, FDG PET and *H MRS, for di­
rect comparison of glycolytic rates and lactate levels in 
4 children, 2 of whom had biochemical evidence of 
impaired mitochondrial respiration.
Materials and M ethods
This study was performed in accordance with the policies of 
the Ethics Committee of the Medical Faculty of Cologne 
University. With the informed consent of parents, all patients 
were initially examined with PET and MRS under the tenta­
tive diagnosis of a congenital metabolic disturbance. 
values were compared with literature data for normal chil­
dren of birth age to 1 year and '1 to 2 year [12], as listed in 
Table 1. MRS data of patients were compared with MRS 
data obtained in children without neurological disorders [13]. 
Amino acid screening in urine was performed using thin- 
layer chromatography, or quantitatively in urine and serum 
using a reverse-phase high-performance liquid chromato­
graphic (HPLC) method. Urinary organic acids were deter­
mined quantitatively using gas chromatography and identified 
by gas chromatography—mass spectroscopy. Lactate, pyru­
vate, (i-hydroxybutyrate, acetoacetate, and carnitine concen­
trations were measured enzymatically. Final diagnosis was 
based on clinical history, physical examination, imaging stud­
ies, laboratory tests, and pathology.
vate dehydrogenase complex, and citrate synthetase were 
measured in skeletal muscle specimens (taken from musculus 
quadriceps femoris) at the Department of Pediatrics, Univer­
sity Hospital Nijmegen, The Netherlands, using the proce­
dures described by Fischer and colleagues [14] and Korenke 
and associates [15].
Mitochondrial Studies
Enzyme activities of cytochrome c oxidase, N A D H :Q [ oxi- 
doreductase, succinate:cytochrome c oxidoreductase, pyru­
Positron Emission Tomography
CMRgic was studied using FDG PET [ 16] on a 7-slice posi­
tron camera (Scanditronix PC384) with an in-plane resolu­
tion of 7.8 mm at a slice thickness of 11 mm or, in one 
case (Patient 3), on a 47-slice camera (Siemens-CTI ECAT 
EXACT 921) with 6-mm transaxial and 5-mm axial resolu­
tion. After a rapid intravenous bolus injection of FDG 
(3.7—7.4 MBq/kg of body weight), patients were scanned for 
a total period of 50 to 60 minutes in a dimly lit room with 
low ambient noise. Images were recorded with the 7-slice 
scanner in two table positions from 30 to 40 and 40 to 50 
minutes after injection, respectively, yielding a total of 14 
slices comprising nearly the entire brain; whereas with the 
47-ring scanner, the whole brain was assessed without chang­
ing the table position from 20 to 60 min. Plasma activity 
was measured in multiple arterial blood samples. CMR^c was 
calculated pixel by pixel with rate constants K\ and ad­
justed to measured tissue activity [17], and a fixed lumped 
constant value of 0.42.
All images were initially analyzed visually. Each image was 
then coregistered three-dimensionally to a reference PET im­
age in standard position (transaxial plane parallel to the inter- 
commissural line) using a multipurpose match program [18] 
with striatum and thalamus as major landmarks. Regions of 
interest (ROIs) were placed on multiple transaxial slices using 
a PC adaptation of an interactive mapping program [19], 
guided by the atlas of Matsui and Hirano [20], and CMR„k 
was calculated for major brain structures including cerebral 
lobes, caudate nucleus, lentiform nucleus, thalamus, cerebel­
lar cortex, and brainstem.
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Table 2. Metabolic Laboratory Values (Ranges of Values Obtained During Course of Patient Hospitalization)
Normal Case 1 Case 2 Case 3 Case 4
Serum lactate (mmol/L) 0.6- 2.4 2.0—5.0 2.5-4.4 3.5-11.2 0 vo 1
CSF lactate (mmol/L) <1.5 2.6 4 .1- 8.0 7.7 0.7-1.5
Urine lactate (jxmol/mmol creatinine) <100 84-112 a 2,187 a
Serum pyruvate (mmol/L) 0.04-0.06 0.12-0.19 0.06-0.13 0.08-0.18 0.09
CSF pyruvate (mmol/L) 0.04-0.06 a 0.13 a a
Serum lactate/pyruvate ratio <20 16-27 34 68 a
CSF lactate/pyruvate ratio <15 a 30 a a
Serum alanine ((xmol/L) 120-480 80 1,595 508-755 162
"Noe available.
cerebrospinal fluid.
Magnetic Resonance Spectroscopy
MR investigations were performed using a 1.5-T MR system 
(Gyroscan Si 5, Philips). Localized spectra were obtained fol­
lowing conventional MR imaging using a 90—180—180 spin- 
echo sequence with an echo time (TE) of 136 msec. Where 
applicable, additional measurements using echo times of 272 
msec were performed to confirm peak assignment of lactate. 
Repetition times were 2 seconds. The ROIs were determined 
from the MR images and comprised the basal ganglia. The 
obtained spectra were compared with the results of measure­
ments in 11 infants, with postconceptual age of 35 to 132 
weeks, who were classified as neurologically normal and did 
not suffer from known metabolic disorders or other disease 
{21}. Resonances of choline-containing compounds (Cho) at 
3.2 ppm, creatine and phosphocreatine (Cr) at 3.0 ppm, N- 
acetylaspartate (NAA) and related compounds at 2.0 ppm, 
and lactate, if present, at 1.3 ppm (inverted with TE 136 
msec, positive with TE 272 msec) were evaluated. Signal— 
intensity ratios were calculated in the frequency domain from 
the area under the respective signals in the phase-corrected 
real part of the complex MR spectrum. Lactate concentra­
tions were calculated using brain water (Case 3) and the Cho 
signal (Case 2) as an internal concentration standard. A brain 
water content of 80% and a concentration of spectroscopi­
cally visible choline-containing compounds of 2 mmol/L was 
assumed [22], The metabolite resonances were corrected for 
relaxation and saturation effects.
In  Case 2, additional spectroscopic images were produced 
from a representative slice of 2.8-cm thickness using a combi­
nation of localized excitation and phase-encoded acquisition, 
applying 32 x 32 phase-encoding steps over a field of view 
of 225 X 225 mm. The data can be presented as maps repre­
senting the distribution of specific biochemical compounds 
with a nominal in-plane resolution of 7.0 mm, or as sets of 
spatially resolved spectra, to allow a more precise evaluation 
o f specific foci of interest. Technical details have been de­
scribed elsewhere [23].
For PET and MRS studies, patients were sedated using pen­
tobarbital with an initial dose of 3 mg/kg of body weight fol­
lowed by 1 to 2 mg/ kg of body weight per hour intravenously.
totic movements. Parents were consanguineous (Grade 
I). At the age of 1.5 years, he had severe psychomotor 
delay and a spastic paraplegia. Laboratory evaluation 
demonstrated an elevated lactate level (Table 2); how­
ever, a pyruvate loading test demonstrated a normal 
pyruvate clearance from blood, which indicates normal 
pyruvate metabolism [24]. MRI at 20 months showed 
increased signal on the T 2-weighted image and de­
creased signal on the T r weighted image in the lateral 
putamen. MRS was normal. PET at 20 months re­
vealed a global decrease in glucose metabolism with 
markedly decreased values in the caudate nuclei, lenti- 
form nuclei, thalamus, and frontal cortex (see Table 1, 
Fig 1). Electrophysiological studies were without ab­
normality. A muscle biopsy was unremarkable and no 
mitochondrial abnormalities were found (Table 3). An 
analysis for chromosomal defects was negative. The 
patient’s condition progressively worsened and he died 
at the age of 2 years due to sepsis. The final clinical 
diagnosis was cerebral palsy due to an unidentified 
metabolic disorder. The lactic acidosis was probably 
caused by severe physical stress and exercise. Brain 
autopsy revealed a symmetrical glial poliodystrophy of 
cortex.
Case 2
The patient was the daughter of consanguineous parents 
(Grade I), born at term after normal pregnancy and 
delivery. At the age of 3 months she suffered a general­
ized seizure. At 5 months, she began having recurrent
Table
psychomotor retardation, 
movements, optic atrophy, and severe muscular hy­
potonia. MRI at 4 months showed cortical atrophy 
and widening of the cerebrospinal fluid (CSF) spaces. 
MRS of the right basal ganglia displayed decreased
NAA
Patients and Results
Case 1
T he patient was a normal boy until the age of 3 months 
when he developed progressive hypotonicity and athe-
creatmecompounds (NAA/Cho), normal ratio 
and phosphocreatine to choline-containing compounds 
(Cr/Cho), and large signals from lactate (3 ± 1 mmol/ 
L). Metabolite maps of a 28-mm-thick slice comprising
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Fig 1, Transaxial metabolic maps at the basal ganglia level of 
all 4 patients obtained with 2-{!sF}fluoro-2-deoxyglucose posi­
tron emission tomography. The individual range of values (in 
fxmoll 100 gmlmin) displayed with a rainbow scale is shown be­
low each image, (Top row) Cases 2 and 3 with mitochondrial 
enzyme disorder and increased CM Rg/v, most pronounced in the 
basal ganglia. (Bottom row) Cases 1 and 4 without evidence of 
mitochondrial impairment and low metabolism.
the basal ganglia demonstrated increased lactate in the 
entire volume (Fig 2). Evaluation with PET (see Fig 
1) at 14 months showed remarkably increased meta­
bolic rates of glucose in all regions, with the largest 
increases in the caudate nuclei, lentiform nuclei, and 
parietooccipital cortex (see Table 1). Evoked potential 
(EP) studies were abnormal. Electroencephalogram 
(EEG) was slow without focal abnormalities. Electro­
myography (EMG) and nerve conduction velocity 
(NCV) examinations were normal. A muscle biopsy 
revealed a mild nonspecific myopathy. Analysis of mi­
tochondrial respiratory chain enzymes revealed a de­
fect in complex IV (cytochrome c oxidase). The pa-
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Table 3. Activities of Respiratory Chain Enzymes and Pyruvate Dehydrogenase Complex
Succinate : Pyruvate
Case Cytochrome c NADH : Qi Cytochrome c Dehydrogenase Citrate
No. Diagnosis Tissue Oxidase Oxidoreductase Oxidoreductase Complex Synthetase
1 Cerebral palsy 
(lactic aci­
dosis due 
to physical 
stress)
Muscle, frozen 81 27 7.5 3.0
4
86
2 Possible com­
plex IV de­
fect
Muscle, frozen 67 16 9-7 4.6 113
3 Complex I de­ Muscle, fresh 78 1.1 22 1.6 40
fect Livera 59 1.7 n.d. n.d. 23
Braina 117 0 n.d. n.d. 223
4 Congenital ep­
ilepsy syn­
drome
No biopsy 
taken :
Normal range Muscle, frozen 52--186 8.9-27 8.2-44 2.7—8.2 48-162
Muscle, fresh 68--437 4.4—26 22-88 2.7-S.2 48-162
Liver 13--108 4.7-9.2 ----------------- — 13-96
Brain 26--181 5.1-19 ----------------- — 53-207
Enzyme activities given in milliunits per mg protein (600 g of supernatanc was used in case of fresh muscle; total homogenate was used in case 
of frozen muscle). Citrate synthetase was used as mitochondrial reference enzyme.
“Denotes post-mortem tissue.
n.d N o t determined.
tient’s condition deteriorated rapidly at the age of 18
thereafter
cardiovascular
formed
Case 3
The patient was a term male newborn delivered spon­
taneously to consanguineous parents (Grade I) after an 
uncomplicated pregnancy. On the fifth day postpartum 
he developed hypotonia as well as increasing hypergly­
cemia and metabolic acidosis. He eventually required 
mechanical ventilation secondary to increasing respira­
tory insufficiency. At 7 days, he developed a severe 
lactic acidosis (see Table 2) and suffered generalized 
seizures. Magnetic resonance imaging (MRI) at 2 
weeks revealed increased signal intensity predomi­
nantly on T2-weighted images in the frontal lobes. 
MRS of the basal ganglia (Fig 3) revealed markedly 
decreased NAA/Cho and Cr/Cho ratios with a large 
lactate signal (8 ± 1 mmol/L). PET at 2 weeks demon­
strated globally elevated CMR^c in all regions with the 
largest increases in the thalamus, caudate and lenticular 
nuclei, and brainstem (see Table 1). EP studies sug­
gested a generalized central nervous system (CNS) dis­
turbance. EEG showed highly irregular background ac­
tivity with superimposed multifocal epileptic foci. 
Muscle biopsy was normal. Analysis of mitochondrial 
respiratory chain enzymes in skeletal muscle, and post­
mortem studies of liver and brain tissue, revealed a
defect in complex I (NADH—coenzyme Q t oxidore- 
ductase) (see Table 3). A chromosome analysis was 
unremarkable. The child experienced a rapid decline 
during the third week and died on his 24th day due to
cardiovascular collapse. Neuropachological examina­
tion revealed symmetrical spongy necrotizing lesions 
in both hemispheres, the basal ganglia, the thalamus, 
and the lower brainstem.
Case 4
The patient was the daughter of nonconsanguineous 
parents, born at term after an uneventful pregnancy 
and delivery. On the second day postpartum, she began 
experiencing cyanotic episodes that progressively in­
creased in frequency and later became associated with 
tonic—clonic movements of the arms and legs. Seizure­
like episodes decreased after the patient was treated 
with corticotropin (ACTH). She had hypotonia, tachyp­
nea, and increased respiratory tract sections. Labora­
tory tests were essentially normal. MRI was unremark­
able. MRS showed no abnormal metabolism products, 
but compared with other signals, NAA signal intensity 
was below normal level. PET at 1 month revealed a 
normal metabolic rate of glucose in all regions except 
for mildly decreased rates in the thalamus (see Table 
1). Upon visual evaluation there was an area of in­
creased metabolism in the right mesiotemporal region 
that could have represented an epileptic focus. EEG 
showed multifocal spikes with alternating areas of focal
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I
[ppm]
c
B
Fig 2. lH  Magnetic resonance spectroscopic study of Patient 2. 
(A) Axial proton density-weighted image ivith volume of interest 
(VOI) indicated. (B) Lactate map within VOL The numbers in-
of
the frontal border of the
from contaminations by signal of retroorbital and skull fat.
(C) Selected spectra demonstrating lactate as a doublet peak with 
a relative maximum in locations 8 and 9/ whereas the broader 
signal at the same position in locations 1 and 16 indicates con­
taminations from fat.
epileptic activity in the right and left rolandic area. All 
other neurophysiologic studies were normal. A muscle 
biopsy and chromosome analysis were both normal. At 
4 months she experienced a rather rapid decline chat 
was accompanied by tachycardia and tachypnea. There 
was a gradual increase in her arterial Pco2 over several 
days, which eventually required intubation, 
after intubation she developed asystole, which was re­
fractory to all resuscitative measures. Brain autopsy re­
vealed a right-sided frontoparietal polygyria as well as 
a moderate enlargement of the ventricular system. N e­
crosis was found in the area of the thalamus, lower 
brainstem, and bilateral occipital lobes.
Discussion
Results obtained from PET measurements on cerebral 
glucose metabolism and MRS provide evidence that 
patients with congenital lactic acidosis due to mito-
356 Annals of Neurology Vol 37 No 3 March 1995
Lac
to the massive increase of metabolism observed in Pa­
tient 3 with its maximum in the basal ganglia.
The extent of increase in the metabolic rates may 
depend on the type and severity of defect {26}.'The 
substantially higher rates of glucose metabolism and, 
correspondingly, the higher cerebral lactate concentra­
tion in Case 3 compared with Case 2 agree with the 
much more decreased activity of the respiratory chain 
capacity in Case 3. The cytochrome c oxidase activity 
in Patient 2’s muscle was reduced only when expressed 
per citrate synthetase activity. In fibroblasts this en­
zyme showed a normal activity.
Glucose uptake and lactate accumulation are two as­
pects of glycolysis. The large resonance peaks for lac­
tate in Cases 2 and 3 show that high amounts of lactate
were present in brain tissue but not in Cases 1 and 4. 
There was some contamination from CSF lactate signal, 
because the volumes of interest (VOIs) also contained
3.7500 3.0000
1
2.2500
---- j—
1.5000 .75000 .00000
[ppm]
parts of the ventricles (9% and 4% of total VOI in 
Cases 2 and 3, respectively). CSF concentrations mea­
sured by lumbar puncture (see Table 2) were in the
Fig 3- Magnetic resonance spectrum of the basal ganglia re­
gion of Patient 3, obtained with an echo time of 212 msec. Cre­
atine (Cr) and N-acetylaspartate (NAA) signals show only half 
the intensity of that in healthy controls. The largest signal origi­
nates from lactate (Lac). Cho =  choline-containing compounds.
same range (3—8 mmol/L) as values in the whole VOI, 
indicating that there were no large differences between 
tissue and CSF concentrations, and that the error of 
tissue concentration measurements due to CSF con­
tamination was small. Presence of lactate in the MR 
spectra seems to correlate with increased FDG uptake.
This indicates that in these cases accumulated lactate is
chondrial defects may have a globally accelerated state 
of cerebral glucose metabolism with relatively higher 
rates of metabolism in the thalamus and basal ganglia. 
Such high rates of metabolism are probably due to a 
change in the utilization of glucose: the cell’s demand 
for energy cannot be covered by defective oxidative 
phosphorylation but initiates the glycolytic pathway in 
which glucose is catabolized to lactate for the produc­
tion of ATP. To compensate for the smaller yield of 
ATP per molecule of glucose from this process, the 
rate of glucose breakdown has to be much higher. The 
massive increase of glycolysis was observed in spite of 
a possible reduction of physiological C/VIi^k. due to 
sedation.
The relatively higher rates found in the basal ganglia 
and thalamus probably reflect the maturational changes 
in metabolism that are seen during early brain develop­
ment. Chugani and co-workers [12] described that the 
developmental increases in CMjRgk occur initially in 
the thalamus, the basal ganglia, and the sensorimotor 
cortex. Thus, the higher rates seen in these areas prob­
ably result because these structures begin developing 
first and express their defect earlier than other sur­
rounding structures. In principle, cortical epileptic dis­
charges, as recorded by EEG in Patients 3 and 4, could 
also contribute to the increase of C/Vfi?glc. In absence 
of an epileptic seizure such epileptic discharges may 
lead to small cortical hypermetabolic foci [25], but not
a consequence of increased glycolysis and does not re­
sult from impaired lactate clearance. In addition, the 
reductions in NAA in both Cases 2 and 3 suggest a 
process of ongoing neuronal damage. The low NAA 
signal in Case 4 may indicate neuronal damage or de­
layed myelination as a consequence of experienced cy­
anotic episodes.
Previous PET studies in adults with mitochondrial 
disorders showed globally decreased rates in metabo­
lism [3, 5, 6]. Two of these studies also demonstrated 
relatively larger decreases in the thalamus [5, 6] and 
basal ganglia [5]. Most likely that type of hypometabo- 
lism is the result of chronic brain damage. A similar
was seen in our 1. Chronic energy
ure has in a recent UP MRS study [27].
In one study [5] oxidative metabolism was compared 
with glucose metabolism and oxidation turned out to 
be relatively more impaired than glycolysis, probably 
still indicating increased nonoxidative glycolysis in that 
chronic stage. Possibly, our Patients 2 and 3 had a more 
severe form of the disease with a massive increase of 
glycolysis that could not be maintained for a long time. 
Theoretically, massive lactate accumulation could exert 
toxic effects [28] and thus contribute to the unfortu­
nate outcome; but increased cerebral lactate signals 
have also been described in chronic cases of mitochon­
drial encephalomyopathies [29].
PET and MRS now are able to demonstrate ; mec-
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abolic consequences of impaired mitochondrial respira­
tion noninvasively in brain tissue. Although mitochon­
drial diseases usually can be diagnosed by biochemical 
analysis of muscle biopsies, the severity of impairment 
may be different in muscle and brain, as indicated by 
our Case 2. Furthermore, the severeness of the clinical 
symptoms is often not well correlated with the residual 
activity of the affected enzyme. Therefore, with further 
experience, the imaging techniques may possibly pro­
vide an estimate of the severity of brain involvement 
and may permit diagnosis also in cases with little or 
no muscle involvement. In addition, effectiveness of 
therapy could be investigated by these techniques.
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